{"ticker": {"uuid": "7abc821a-17ab-461e-baa3-1675cf3c88d6", "symbol": "POLB", "name": "Poolbeg Pharma PLC", "exchange": "LSE", "country": "GB", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Poolbeg Pharma Secures \u00a33.5m to Advance Cancer and Obesity Programmes (POLB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNb0xQejFHVUx6cjJvZ3hiUVZXdThPd1NfUVhTZllKZXpYXzJodFUwUW4yOWZabnZnN2dLYk5rLTNuMmpWWm9PRklHa3NMUl9VWUZpZ1ltd3JyNEs1dXlXNTM4cjFVNHhGcmhBZXdxRWNOdk9aV1IwY1JUZTZURVl0STFB?oc=5", "source_name": "Market source", "published_at": "2026-07-14T07:15:19+00:00", "published_display": "14 Jul 2026 07:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Poolbeg Pharma PLC - Placing to raise \u00a33.5 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOdjhudUNoWmNTN29TQ3RzSG15eU5kVjdfOHFWRElsRVJUaURtdS1WMkpXMnNFQjgyUlFsVGNfYnRReG9meUQ5M091ZWsyaTgyeXE5V2czR1VpaGtMTWp3bjV4THVtbElFSkZMQUdva09VUnkyN3phZ1EtODFsUEVVS0UxcHVUTUVWQXhxYU03VVQ2aW9XcDZmcUdTUjFONDZlb1l6MDhJOFo2RGR4QVdzZExRaGlONVFkQ1JOaDhmRGNSSHE2ZUE?oc=5", "source_name": "TradingView", "published_at": "2026-07-14T06:00:00+00:00", "published_display": "14 Jul 2026 06:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discover UK Penny Stocks: Poolbeg Pharma And Two More Top Picks", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T13:12:28+00:00", "published_display": "10 Jul 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Poolbeg Pharma PLC \u2013 LSE:POLB", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPR1o0MkRpTjBWTk1LMWZnNGR6VHZSSlZIbExRSTl4TU1kNF9vZ29OcEU4X21BTmFCUWlpZE1mV2dzekdmLTJxWHpPV3hlcVlSblNlenNfWFR0Vk9OcWY5N0NhRE5UcnB6WjZ1Sm1hQU9pNkJRR1BLS2U0UDJqbnV3OHBGTUp1bi13eDQtblA4RWFMbXQtSnEwNGtB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T01:20:11+00:00", "published_display": "02 Jul 2026 01:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxQSzZJbjEwcGY5alpkdkpCNnBnSlNMTTQ2czBaWWhCaGVtRlNfQnVJMm5CMFlLSFY3TUsyZGIwdXZWdmJiZmtsN2FBWE5SdFJEcmhaNWZBTFpDZDkzSHVHcFJRVmJudElKMlRxVDhuaHluVkQ0ci0yVFVHZGlmMHJ5em9mRU5HVVVVczVKSEo2Y3pMVDR5NF9OWTY2c1VFalRqeHhzLWtUNHlWRkxoc3NNQ0NsZVEwMG1NLUZheU56VFJyNjhmWG1VN2RCek8xQkdCNkNoYmRRamYyTHdycll1MFVlZ1hJZjN3Q2FlRzVaRm1Xc0hxZVVJWEZSNA?oc=5", "source_name": "Proactive Investors", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma receives European patent for POLB 001 in CRS By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSkR4c0ZrYngzd2JXdG5Wc3ktT040TmZBRUc3eWR4LWtoNUJWem9SSFBpQU5sUDNqTmFVbW9hU1ZGNjJCMkV6QmlRdWcySTVBaThBUDUwUURmRFdja0lNTWZ3REFHZDVvS2FXZ3UtWndsdTlKaE5KUEhwTVU5cElRNTRyZW15QTlfai0tYkRMTjdpU3puQXdhT2lhVEpnbHlRQ1FnQTVUQ3F4Y3RPRGs1X2lack5BbEctTExsUw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma PLC (AIM: POLB) Preclinical data posters presented at EHA Congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTDB5TUwyeC1FRjdzaWlwNDExSHl2TGRUbHpCd1llZThfN2VuTnFmeWtHeDRGRENaRnVCSG41dWhoeGFzZ2JNY0h5X2FSNHRDaEIzLU9PY1dSY2FkVUQxellvN0E1STRTNlRmQ3BIZEhaYmFZVHBKNkg1dlpuZTM2dFB0MXVualBBRFN4MWY1ZDNZNjZmdUtnc3VpY1ZZcTZlQ2U5aUZ6X3AyZw?oc=5", "source_name": "Share Talk", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma shareholders approve AGM resolutions By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPSGV5azVsT3FmbkRBalRnM1RlUnZRcnNSR1M3QXBKQzltTjFfNnh4ODltZ3BwRXYyZGg0ZWZsZ0FxTE5DdTFxYjY2VEpQWENYNjRSTGI1VHI1YWV0dU12UkswVExBLWxQQ2g0OHprbEJ2RUNqR0RFaWJDc05jcGZGeDQ5RXJwSHhLRjlNYkg5T21URTg0UzBtN2FuNDB3X0JRRmdvZEFEeVVyaFpRdnkzbUR3?oc=5", "source_name": "Investing.com UK", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma (AIM: POLB) Pre-IND Meeting with the FDA for POLB 001", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNZC0yekxaS2pYaHQ3ZnhSUUF5VHJwZFg1NzlwYS02Q1lTVWF0ZXA1ZUZkaTExenBuWno2eW9ENnhwOXZNd1VNMnVYR211NGNtUjJORGEyc2JxMjZrLUxlVURDZHA2cWluOFhUZFdub0xKZTVtQi1PNHpSZExnSUVTVF9vdFBPeW9nWUFnQzI1UW92QnZuQ3FiVA?oc=5", "source_name": "Share Talk", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg eyes transformative summer with POLB 001 data in prospect", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQR1JMYVNXX2Y2a2J0bmYyYjBlMkhOd09LMEU2elpsRGgwOUt2OFFtM19mYnpfSElVcEl0ZWtWUk4tckJENTVoVmRobUR4SmI3YWU2M2oyNlVCenlnR1ZqVWpnemVTNlJXSUEtUFg0b3BFa3VFVER3ZXlKaU5IRklDcUN6eXdfSVpUZjBha2RramhPUQ?oc=5", "source_name": "Yahoo! Finance Canada", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma advances POLB 001 into UK trial - ICYMI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOaTdyVmg5anFFajFyTEU2X0tyejlYWkp5ZDZUNndrSjVuZVV4TksyMHk0c1ZwQURDQ3VpZUZ5cFFLRHJic2dxbzl0WUplNlZvNm5OcDdnNUFYZDNVR1NkaFpUMDVKYXY1UFR2TTl4QklCbkRsQmZ0NlFsVUYtSFZIRG51NlR3dXgtYjFLa1o5ZWllU2F6MWs5YkNNQkk2Skl2MHdDMC1WZ0hsSmFiX1FXTG90aGJhcnA5RE1CclpUT0JpTG8?oc=5", "source_name": "Proactive Investors", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why 2026 could be a defining year for Poolbeg Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQUnVnc0E5bHVpNlBqdTZ5U1pwM2pPazFvOWFWbTk2ZGp0V1RkakdRei1LVlhhY3E1RmpiWUZFTmZMb1NRaXFIMkJPdzBpTEF4c2pHaklhbWlKU09ac0o4aGZVbkN0dmF4bzluRXZkR2dPNjh1MldINkxBOFI5bVBHU0FpcUs3QUtOeXc?oc=5", "source_name": "Share Talk", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma receives UK clearance to begin cancer immunotherapy trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOR1VqWjZMc1FtVGIwQU1lcG9XVWs4ZTJ2VGlTUU1UQUljcGVlUEJPTlR6U1pKSDl0V044VmVaY2x5dUU4VFV1eWNOWDNxZmNJYWVXYURQSEg5TVE5ZTdib2ZObTdOSUcwUklzMWpUTzNJQl8zUy0zMEJxYndLVUR5eFJyRVhHbVhDT05DQkJ2NkNCWENWUjZjRVZZZHhFZEoybGc?oc=5", "source_name": "Share Talk", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma (AIM: POLB) Significant milestone for Poolbeg\u2019s IP portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNcmU3WmIwTnNIRzdkdHRFeVpkVXc2TlIweXdPZkgweWNTUl9HYU9ueE5NUDFDcUUzMmtLdlNBaUpMM2UzbVZldTNPcnJGOGowQy1lcnUxblRoV2hKY2Nxajl4OXdZSXplZnluNHFNUi1HU1c3czBHdTQtckFRZmcyRGw4UDAwM2poWVhwMWtRRmszUTluSDZuLUhqR1pmcWVk?oc=5", "source_name": "Share Talk", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma shares rise 10% as Australian patent grant bolsters POLB 001 commercial appeal", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPS2pEUUdlTFFHRkpUUzBySlJOV2paX0t2bjVxZGdCS3NXamJDeEU5eUZRRUdrZ0g3Y21GNFl1NXBnZkdYcjFHMEVLYjRQNG9pQ2l5c3VFQXR2c0lISnhqS2RUdkFCYnUxYzdxQklENUR6Sk9QT0JIMDBfazJVdm9PdDVUdlV4elRnRUxhdVNscjVzcktEZmZBdkpfSU9BOXc?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma plc (\u201cPoolbeg\u201d or the \u201cCompany\u201d) Combination of Poolbeg and HOOKIPA Pharma Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOTy1UaGh4eVdEdW5ETG0tVTF4MmFncHl1LWhTVHZ4ZXR3UVVWSjNieTYtcTA0NVdTUEVkcDVhQTFuTmVwMVIzZ0RUYUVVOG9MV2pyaC1vRE5jVUh2Y3ZUV3I0Uk9BNTRWUnJQcVVRS3k4SFZhU19leHhUQVljMEdncDB5T2N4LWRMUklBaWdPMGphY1FCOGVEV2UtLUhGdlJGZlhUZ0hVdWlOQTlXeTd3SnhnQjNnUnlfTVI0TjctQmVNOFdMYmxPTk9HYUMycXVzOGVkNDl5TVBBRmZwRDVvVzluMy1JZ0hMWkxXYWNtVFM?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-01-02T08:00:00+00:00", "published_display": "02 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Poolbeg Pharma Secures \u00a33.5m to Advance Cancer and Obesity Programmes (POLB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNb0xQejFHVUx6cjJvZ3hiUVZXdThPd1NfUVhTZllKZXpYXzJodFUwUW4yOWZabnZnN2dLYk5rLTNuMmpWWm9PRklHa3NMUl9VWUZpZ1ltd3JyNEs1dXlXNTM4cjFVNHhGcmhBZXdxRWNOdk9aV1IwY1JUZTZURVl0STFB?oc=5", "source_name": "Market source", "published_at": "2026-07-14T07:15:19+00:00", "published_display": "14 Jul 2026 07:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REG - Poolbeg Pharma PLC - Placing to raise \u00a33.5 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOdjhudUNoWmNTN29TQ3RzSG15eU5kVjdfOHFWRElsRVJUaURtdS1WMkpXMnNFQjgyUlFsVGNfYnRReG9meUQ5M091ZWsyaTgyeXE5V2czR1VpaGtMTWp3bjV4THVtbElFSkZMQUdva09VUnkyN3phZ1EtODFsUEVVS0UxcHVUTUVWQXhxYU03VVQ2aW9XcDZmcUdTUjFONDZlb1l6MDhJOFo2RGR4QVdzZExRaGlONVFkQ1JOaDhmRGNSSHE2ZUE?oc=5", "source_name": "TradingView", "published_at": "2026-07-14T06:00:00+00:00", "published_display": "14 Jul 2026 06:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discover UK Penny Stocks: Poolbeg Pharma And Two More Top Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNNkhxLW5WcURLWVotdjJRQTBzRVBlTWtOZzg4UXJkem9iUWhVZXR0c09kNUNnQ1FxdGVobEoxSDlubkxfb0JNQ2JSREZzSU1XelM1aUdSNmZRSEMxeDRudURsQmJqdDNxWHoyYmVocjVHSFVJTThzUlZ3MnM2ZDVuMURUempoVWYtcFpLbHd1aDhiaDNJYnd6ekVpX0Nkd2c1aUlSbXo4N2RYNnlNcGpubFVxYzZwSFloSC1NdENkeXUxNzlmQlFnRXQ0ek9Ya0tRQ1o0NmFNSEhGZ05adXY0eTFvTWJpemvSAewBQVVfeXFMTTNaVUFlNXpSanpUOGhNOVR1VzRhanpyTTYxUEhEOGF4YWxJRkl2NDRiYWFXTlRSa0lVLUVodi1teDZ5a1BuWlcwWnFhN1dzT3RKcjZmNE9jX091V0d0Q2FURnNhcDZBU243eTM3aGJRMUdNZUpsYUMzQjhaM3NaZUMwcy1fa3pnU3hrLUprdUI1anp5bTZYV1pDcXZXQzloNjZJWHdXZHdPMHRKSkxxU2FzX05sWkZnQUhBN3hCdDJSOVNzellYSW5nUUg4ZDlHXzIxaF9ySVJJcWlQOHRDdFdZQUF1UWsweG92Zmk?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T13:12:28+00:00", "published_display": "10 Jul 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Poolbeg Pharma PLC \u2013 LSE:POLB", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPR1o0MkRpTjBWTk1LMWZnNGR6VHZSSlZIbExRSTl4TU1kNF9vZ29OcEU4X21BTmFCUWlpZE1mV2dzekdmLTJxWHpPV3hlcVlSblNlenNfWFR0Vk9OcWY5N0NhRE5UcnB6WjZ1Sm1hQU9pNkJRR1BLS2U0UDJqbnV3OHBGTUp1bi13eDQtblA4RWFMbXQtSnEwNGtB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T01:20:11+00:00", "published_display": "02 Jul 2026 01:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxQSzZJbjEwcGY5alpkdkpCNnBnSlNMTTQ2czBaWWhCaGVtRlNfQnVJMm5CMFlLSFY3TUsyZGIwdXZWdmJiZmtsN2FBWE5SdFJEcmhaNWZBTFpDZDkzSHVHcFJRVmJudElKMlRxVDhuaHluVkQ0ci0yVFVHZGlmMHJ5em9mRU5HVVVVczVKSEo2Y3pMVDR5NF9OWTY2c1VFalRqeHhzLWtUNHlWRkxoc3NNQ0NsZVEwMG1NLUZheU56VFJyNjhmWG1VN2RCek8xQkdCNkNoYmRRamYyTHdycll1MFVlZ1hJZjN3Q2FlRzVaRm1Xc0hxZVVJWEZSNA?oc=5", "source_name": "Proactive Investors", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma receives European patent for POLB 001 in CRS By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOSkR4c0ZrYngzd2JXdG5Wc3ktT040TmZBRUc3eWR4LWtoNUJWem9SSFBpQU5sUDNqTmFVbW9hU1ZGNjJCMkV6QmlRdWcySTVBaThBUDUwUURmRFdja0lNTWZ3REFHZDVvS2FXZ3UtWndsdTlKaE5KUEhwTVU5cElRNTRyZW15QTlfai0tYkRMTjdpU3puQXdhT2lhVEpnbHlRQ1FnQTVUQ3F4Y3RPRGs1X2lack5BbEctTExsUw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma PLC (AIM: POLB) Preclinical data posters presented at EHA Congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTDB5TUwyeC1FRjdzaWlwNDExSHl2TGRUbHpCd1llZThfN2VuTnFmeWtHeDRGRENaRnVCSG41dWhoeGFzZ2JNY0h5X2FSNHRDaEIzLU9PY1dSY2FkVUQxellvN0E1STRTNlRmQ3BIZEhaYmFZVHBKNkg1dlpuZTM2dFB0MXVualBBRFN4MWY1ZDNZNjZmdUtnc3VpY1ZZcTZlQ2U5aUZ6X3AyZw?oc=5", "source_name": "Share Talk", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma shareholders approve AGM resolutions By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPSGV5azVsT3FmbkRBalRnM1RlUnZRcnNSR1M3QXBKQzltTjFfNnh4ODltZ3BwRXYyZGg0ZWZsZ0FxTE5DdTFxYjY2VEpQWENYNjRSTGI1VHI1YWV0dU12UkswVExBLWxQQ2g0OHprbEJ2RUNqR0RFaWJDc05jcGZGeDQ5RXJwSHhLRjlNYkg5T21URTg0UzBtN2FuNDB3X0JRRmdvZEFEeVVyaFpRdnkzbUR3?oc=5", "source_name": "Investing.com UK", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma (AIM: POLB) Pre-IND Meeting with the FDA for POLB 001", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNZC0yekxaS2pYaHQ3ZnhSUUF5VHJwZFg1NzlwYS02Q1lTVWF0ZXA1ZUZkaTExenBuWno2eW9ENnhwOXZNd1VNMnVYR211NGNtUjJORGEyc2JxMjZrLUxlVURDZHA2cWluOFhUZFdub0xKZTVtQi1PNHpSZExnSUVTVF9vdFBPeW9nWUFnQzI1UW92QnZuQ3FiVA?oc=5", "source_name": "Share Talk", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg eyes transformative summer with POLB 001 data in prospect", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQR1JMYVNXX2Y2a2J0bmYyYjBlMkhOd09LMEU2elpsRGgwOUt2OFFtM19mYnpfSElVcEl0ZWtWUk4tckJENTVoVmRobUR4SmI3YWU2M2oyNlVCenlnR1ZqVWpnemVTNlJXSUEtUFg0b3BFa3VFVER3ZXlKaU5IRklDcUN6eXdfSVpUZjBha2RramhPUQ?oc=5", "source_name": "Yahoo! Finance Canada", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma advances POLB 001 into UK trial - ICYMI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOaTdyVmg5anFFajFyTEU2X0tyejlYWkp5ZDZUNndrSjVuZVV4TksyMHk0c1ZwQURDQ3VpZUZ5cFFLRHJic2dxbzl0WUplNlZvNm5OcDdnNUFYZDNVR1NkaFpUMDVKYXY1UFR2TTl4QklCbkRsQmZ0NlFsVUYtSFZIRG51NlR3dXgtYjFLa1o5ZWllU2F6MWs5YkNNQkk2Skl2MHdDMC1WZ0hsSmFiX1FXTG90aGJhcnA5RE1CclpUT0JpTG8?oc=5", "source_name": "Proactive Investors", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why 2026 could be a defining year for Poolbeg Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQUnVnc0E5bHVpNlBqdTZ5U1pwM2pPazFvOWFWbTk2ZGp0V1RkakdRei1LVlhhY3E1RmpiWUZFTmZMb1NRaXFIMkJPdzBpTEF4c2pHaklhbWlKU09ac0o4aGZVbkN0dmF4bzluRXZkR2dPNjh1MldINkxBOFI5bVBHU0FpcUs3QUtOeXc?oc=5", "source_name": "Share Talk", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma receives UK clearance to begin cancer immunotherapy trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOR1VqWjZMc1FtVGIwQU1lcG9XVWs4ZTJ2VGlTUU1UQUljcGVlUEJPTlR6U1pKSDl0V044VmVaY2x5dUU4VFV1eWNOWDNxZmNJYWVXYURQSEg5TVE5ZTdib2ZObTdOSUcwUklzMWpUTzNJQl8zUy0zMEJxYndLVUR5eFJyRVhHbVhDT05DQkJ2NkNCWENWUjZjRVZZZHhFZEoybGc?oc=5", "source_name": "Share Talk", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma (AIM: POLB) Significant milestone for Poolbeg\u2019s IP portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNcmU3WmIwTnNIRzdkdHRFeVpkVXc2TlIweXdPZkgweWNTUl9HYU9ueE5NUDFDcUUzMmtLdlNBaUpMM2UzbVZldTNPcnJGOGowQy1lcnUxblRoV2hKY2Nxajl4OXdZSXplZnluNHFNUi1HU1c3czBHdTQtckFRZmcyRGw4UDAwM2poWVhwMWtRRmszUTluSDZuLUhqR1pmcWVk?oc=5", "source_name": "Share Talk", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma shares rise 10% as Australian patent grant bolsters POLB 001 commercial appeal", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPS2pEUUdlTFFHRkpUUzBySlJOV2paX0t2bjVxZGdCS3NXamJDeEU5eUZRRUdrZ0g3Y21GNFl1NXBnZkdYcjFHMEVLYjRQNG9pQ2l5c3VFQXR2c0lISnhqS2RUdkFCYnUxYzdxQklENUR6Sk9QT0JIMDBfazJVdm9PdDVUdlV4elRnRUxhdVNscjVzcktEZmZBdkpfSU9BOXc?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Poolbeg Pharma plc (\u201cPoolbeg\u201d or the \u201cCompany\u201d) Combination of Poolbeg and HOOKIPA Pharma Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOTy1UaGh4eVdEdW5ETG0tVTF4MmFncHl1LWhTVHZ4ZXR3UVVWSjNieTYtcTA0NVdTUEVkcDVhQTFuTmVwMVIzZ0RUYUVVOG9MV2pyaC1vRE5jVUh2Y3ZUV3I0Uk9BNTRWUnJQcVVRS3k4SFZhU19leHhUQVljMEdncDB5T2N4LWRMUklBaWdPMGphY1FCOGVEV2UtLUhGdlJGZlhUZ0hVdWlOQTlXeTd3SnhnQjNnUnlfTVI0TjctQmVNOFdMYmxPTk9HYUMycXVzOGVkNDl5TVBBRmZwRDVvVzluMy1JZ0hMWkxXYWNtVFM?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-01-02T08:00:00+00:00", "published_display": "02 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 87, "total_relevant": 16, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 15, "score": 52, "total": 16, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 95, "events": [{"event": "general", "label": "Market update", "weight": 8.8, "count": 16}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.07, "latest_week": "2026-07-10", "one_week_move": 2.2, "four_week_move": -9.1, "twelve_week_move": 52.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.899465, "market_dynamics_buy_signal": false, "relative_strength": 51.777757, "fair_value_gap": 3.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.9295, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.2% over one week, -9.1% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Share Talk", "count": 5}, {"label": "Market source", "count": 2}, {"label": "TradingView", "count": 2}, {"label": "Proactive Investors", "count": 2}, {"label": "simplywall.st", "count": 1}, {"label": "Investing.com Nigeria", "count": 1}, {"label": "Investing.com UK", "count": 1}, {"label": "Yahoo! Finance Canada", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 16}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 16}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "95/100 classification confidence."}, {"label": "Company focus", "value": "16", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.2% over one week, -9.1% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Poolbeg Pharma Secures \u00a33.5m to Advance Cancer and Obesity Programmes (POLB)"}], "updated_at": "2026-07-17T05:45:14.819178+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}